Taltz ® (ixekizumab) injektion

För fullständig produktresumé för Taltz® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Taltz® (ixekizumab): Affinitetsbindning

Ixekizumab binder med hög affinitet och specificitet vid IL-17A.

Detailed Information

Mechanism of action

Ixekizumab is an IgG4 monoclonal antibody that binds with high affinity (< 3 pM) and specificity to interleukin 17A (both IL‑17A and IL‑17A/F). Elevated concentrations of IL‑17A have been implicated in the pathogenesis of psoriasis by promoting keratinocyte proliferation and activation, as well as in the pathogenesis of psoriatic arthritis and axial spondyloarthritis by driving inflammation leading to erosive bone damage and pathological new bone formation. Neutralisation of IL‑17A by ixekizumab inhibits these actions. Ixekizumab does not bind to ligands IL‑17B, IL‑17C, IL‑17D, IL‑17E or IL‑17F.1 

In vitro binding assays confirmed that ixekizumab does not bind to human Fcγ receptors I, IIa, and IIIa or to complement component C1q.1

  • The association between the binding affinity of ixekizumab and efficacy and safety has not been studied by Lilly.

  • No comparisons can be made regarding the binding affinity of IL-17A to ixekizumab and the binding affinity of other products to their targets. This has not been studied by Lilly.


1. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.


IgG4 = immunoglobulin G subclass 4

IL-17 = interleukin-17

Lilly = Eli Lilly and Company

Datum fӧr senaste ӧversyn 2018 M09 10

Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss